SHPH logo

SHUTTLE PHARMACEUTICALS HOLD

SHPHNASDAQ
🏆 #4771 by market capUS Equity
$3.92▼ $0.18 (−4.62%)
🌙 After hours$3.95▲ 0.77%Regular close · extended-hours price shown
🔔
Track SHPH
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 4.6%
7d▲ 0.5%
14d▲ 12.3%
30d▲ 10.1%
ytd▼ 77.1%
1y▼ 90.0%
🏦Market Cap
$3M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
76
Good

Trading Snapshot

Day Range
$3.87 – $3.96
52-Week Range
$2.58 – $55.90
Volume
$2.92B
Avg Volume
$2.23B
Shares Outstanding
640,000
Next Earnings
Nov 9, 2026

Fundamentals Snapshot

Annual Revenue
$218,157
Last Q Revenue
$57,390
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-27.52
Dividend Yield
—
Dilution (1yr)
−50.4%

Why Investors Own SHPH

  • ✓High-growth profile — revenue up +30.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 59% gross margin and 6% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SHPH logo

SHUTTLE PHARMACEUTICALS HOLD

SHPH
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$12M▲ +54.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$9M▲ +29.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
202K▼ −50.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$102K▼ −$645K YoY
StockOtter · stockotter.space

About SHUTTLE PHARMACEUTICALS HOLD

Shuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy. Its current portfolio of clinical-phase treatments features Ropidoxuridine, an orally administered halogenated pyrimidine, which is intended for individuals afflicted with brain tumors and soft tissue sarcomas. Additionally, the company is progressing Doranidazole, an injectable compound designed to make oxygen-deprived tumor cells more responsive to radiation, targeting malignancies of the pancreas, lungs, and liver. This enterprise was established in 2012 and maintains its principal operations in Rockville, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Price Target

ⓘ
Average Target
$4.13
▲ +5.4% Upside
High Target$4.98
Low Target$3.62
Based on 38 analysts

Latest News & Updates

Newsfile Corp·Aug 28

Shuttle Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance Letter

Gaithersburg, Maryland--(Newsfile Corp. - August 28, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) (the "Company" or "Shuttle"), today announced that the Company is not in compliance with the periodic fil

Defense World·Jul 22

Daiichi Sankyo (OTCMKTS:DSNKY) & Shuttle Pharmaceuticals (NASDAQ:SHPH) Head to Head Contrast

Shuttle Pharmaceuticals (NASDAQ: SHPH - Get Free Report) and Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the